Ingrid A. Mayer, MD, MSCI

Mayer believes it is not yet known who benefits from these targeting agents. There is phase II data for CDK4/6 inhibition in the first-line setting, which is encouraging because the preliminary results showed an improvement in progression-free survival, adds Mayer.

However, the phase III data does not yet have complete mature results, so it is difficult to determine whether or not the combination will yield an overall survival advantage.

Ingrid A. Mayer, MD, MSCI, co-leader and clinical director, Breast Cancer Research Program, chair, Data and Safety Monitoring Committee, associate professor of medicine (hematology/oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).

Videos

Ingrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC). 


Ingrid A. Mayer, MD, MSCI | Authors

Articles

Dr. Mayer Discusses Patient Selection for Emerging Therapies in Patients With ER+ mBC